Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND trial of adjunctive bezlotoxumab in high-risk Clostridioides difficile infection
2021-005473-10Phase 3Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Bezlotoxumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Organ dysfunction definition. Started Oct 2021; status: completed.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2021-005473-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005473-10.